GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Werewolf Therapeutics Inc (NAS:HOWL) » Definitions » ROC (Joel Greenblatt) %

Werewolf Therapeutics (Werewolf Therapeutics) ROC (Joel Greenblatt) % : -420.67% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Werewolf Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Werewolf Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -420.67%.

The historical rank and industry rank for Werewolf Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

HOWL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -686.19   Med: -318.63   Max: -211.96
Current: -240.05

During the past 5 years, Werewolf Therapeutics's highest ROC (Joel Greenblatt) % was -211.96%. The lowest was -686.19%. And the median was -318.63%.

HOWL's ROC (Joel Greenblatt) % is ranked better than
54.72% of 1462 companies
in the Biotechnology industry
Industry Median: -329.055 vs HOWL: -240.05

Werewolf Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Werewolf Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Werewolf Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Werewolf Therapeutics ROC (Joel Greenblatt) % Chart

Werewolf Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-291.55 -686.19 -515.11 -318.63 -211.96

Werewolf Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -275.64 -147.10 -233.01 -175.77 -420.67

Competitive Comparison of Werewolf Therapeutics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Werewolf Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Werewolf Therapeutics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Werewolf Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Werewolf Therapeutics's ROC (Joel Greenblatt) % falls into.



Werewolf Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.677) - (6.569 + 0.907 + 3.627)
=-8.426

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.32) - (6.459 + 0.502 + 1.35)
=-5.991

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Werewolf Therapeutics for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-60.76/( ( (14.846 + max(-8.426, 0)) + (14.041 + max(-5.991, 0)) )/ 2 )
=-60.76/( ( 14.846 + 14.041 )/ 2 )
=-60.76/14.4435
=-420.67 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Werewolf Therapeutics  (NAS:HOWL) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Werewolf Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Werewolf Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Werewolf Therapeutics (Werewolf Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
200 Talcott Avenue, 2nd Floor, Watertown, MA, USA, 02472
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.
Executives
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Luke Evnin director THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116
Meeta Chatterjee director C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Michael A. Sherman director 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Chulani Karunatilake officer: Chief Technology Officer 1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Reid Leonard officer: Chief Operating Officer 1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Mpm Oncology Innovations Fund Lp 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Longwood Fund Iii Gp, Llc 10 percent owner 800 BOYLSTON ST, SUITE 1555, BOSTON MA 02199
Derek Dirocco director 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Moshe Arkin 10 percent owner 6 HACHOSHLIM ST., HERZELIA L3 4672406
Alon Lazarus director, 10 percent owner C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Daniel J Hicklin director, 10 percent owner, officer: See Remarks
Sphera Funds Management Ltd. 10 percent owner 4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Management Lp 10 percent owner 4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Gp Ltd. 10 percent owner 4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520

Werewolf Therapeutics (Werewolf Therapeutics) Headlines